DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: SUBGROUP ANALYSIS OF THE CALM STUDY

被引：1

作者：

Bossuyt, P. ^{[1
]}

D'Haens, G. ^{[2
]}

Panaccione, R. ^{[3
]}

Sandborn, W. ^{[4
]}

Reinisch, W. ^{[5
]}

Travis, S. ^{[6
]}

Schreiber, S. ^{[7
]}

Armuzzi, A. ^{[8
]}

Danese, S. ^{[9
]}

Berg, S. ^{[10
]}

Petersson, J. ^{[11
]}

Maa, J-F ^{[11
]}

Neimark, E. ^{[11
]}

Colombel, F. ^{[12
]}

机构：

[1] Imelda Gen Hosp, Bonheiden, Belgium

[2] Acad Med Ctr, Amsterdam, Netherlands

[3] Univ Calgary, Calgary, AB, Canada

[4] Univ Calif San Diego, La Jolla, CA 92093 USA

[5] Med Univ Vienna, Vienna, Austria

[6] Oxford Univ Hosp, Oxford, England

[7] Univ Hosp Schleswig Holstein, Kiel, Germany

[8] Fdn Policlin Gemelli Univ, Rome, Italy

[9] Humanitas Univ, Rozzano, Italy

[10] AbbVie, Solna, Sweden

[11] AbbVie Inc, N Chicago, IL USA

[12] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

来源：

GUT | 2019年 / 68卷

关键词：

D O I：

10.1136/gutjnl-2019-BSGAbstracts.136

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PTH-077

引用

页码：A70 / A71

页数：2

共 50 条

[21] De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study
Annemiek K. E. van Hemert
Josefien P. van Olmen
Liesbeth J. Boersma
John H. Maduro
Nicola S. Russell
Jolien Tol
Ellen G. Engelhardt
Emiel J. Th. Rutgers
Marie-Jeanne T. F. D. Vrancken Peeters
Frederieke H. van Duijnhoven
Breast Cancer Research and Treatment, 2023, 199 : 81 - 89
[22] Safety of adalimumab in patients with Crohn's disease
Reactions Weekly, 2018, 1708 (1) : 13 - 13
[23] De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study
van Hemert, Annemiek K. E.
van Olmen, Josefien P. P.
Boersma, Liesbeth J. J.
Maduro, John H. H.
Russell, Nicola S. S.
Tol, Jolien
Engelhardt, Ellen G. G.
Rutgers, Emiel J. Th.
Peeters, Marie-Jeanne T. F. D. Vrancken
van Duijnhoven, Frederieke H. H.
BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 81 - 89
[24] Adalimumab as Therapy for Fistulizing Orofacial Crohn's Disease
Doherty, Glen
Kalachand, Roshni
Patchett, Stephen
INFLAMMATORY BOWEL DISEASES, 2010, 16 (02) : 184 - 185
[25] Adalimumab therapy in Crohn's disease of the ileal pouch
Li, Yue
Lopez, Rocio
Queener, Elaine
Shen, Bo
INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) : 2232 - 2239
[26] Adalimumab Therapy for Patients With Crohn's Disease Who Are Unresponsive to or Intolerant of Infliximab
Shafran, I
Burgunder, P.
Fakih, A.
INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S44 - S44
[27] Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn's Disease
Liu, Yifei
Soderberg, Joakim
Chao, Jingdong
PHARMACY, 2022, 10 (04)
[28] Adalimumab maintenance therapy improves quality of life in patients with Crohn's disease
Nature Reviews Gastroenterology & Hepatology, 2009, 6 (3) : 129 - 129
[29] Efficacy and Safety of Adalimumab in Inducing Clinical Remission in Crohn's Disease: A Meta-Analysis With Subgroup Analysis
Aksan, Feyzullah
Tanriverdi, Lokman Hekim
Monzur, Farah
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S735 - S735
[30] Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis
Kopylov, U.
Al-Taweel, T.
Yaghoobi, M.
Afif, W.
Bitton, A.
Lakatos, P. L.
Ben-Horin, S.
Seidman, E. G.
JOURNAL OF CROHNS & COLITIS, 2014, 8 : S50 - S51

← 1 2 3 4 5 →